Napatree Capital LLC Reduces Stock Holdings in Pfizer Inc. (NYSE:PFE)

Napatree Capital LLC reduced its stake in Pfizer Inc. (NYSE:PFE) by 13.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 23,725 shares of the biopharmaceutical company’s stock after selling 3,744 shares during the period. Napatree Capital LLC’s holdings in Pfizer were worth $629,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the business. Swedbank AB lifted its stake in Pfizer by 0.7% in the 3rd quarter. Swedbank AB now owns 5,745,831 shares of the biopharmaceutical company’s stock valued at $166,284,000 after buying an additional 37,636 shares in the last quarter. United Bank increased its holdings in shares of Pfizer by 3.7% during the 3rd quarter. United Bank now owns 35,599 shares of the biopharmaceutical company’s stock worth $1,030,000 after buying an additional 1,277 shares during the last quarter. Segall Bryant & Hamill LLC acquired a new stake in shares of Pfizer during the 3rd quarter worth $2,123,000. Connor Clark & Lunn Investment Management Ltd. increased its holdings in shares of Pfizer by 67.4% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 14,801 shares of the biopharmaceutical company’s stock worth $428,000 after buying an additional 5,959 shares during the last quarter. Finally, Pacer Advisors Inc. increased its holdings in Pfizer by 5.1% in the 3rd quarter. Pacer Advisors Inc. now owns 431,232 shares of the biopharmaceutical company’s stock valued at $12,480,000 after purchasing an additional 20,769 shares in the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, Director Ronald E. Blaylock acquired 19,457 shares of the firm’s stock in a transaction dated Thursday, February 13th. The stock was bought at an average price of $25.65 per share, with a total value of $499,072.05. Following the transaction, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. The trade was a 235.84 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 0.06% of the stock is currently owned by company insiders.

Pfizer Price Performance

PFE opened at $26.20 on Friday. The company’s 50 day simple moving average is $26.17 and its 200-day simple moving average is $27.04. Pfizer Inc. has a one year low of $24.48 and a one year high of $31.54. The stock has a market capitalization of $148.61 billion, a P/E ratio of 18.58, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping the consensus estimate of $0.48 by $0.15. The company had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business’s revenue for the quarter was up 24.7% compared to the same quarter last year. During the same period last year, the business posted $0.10 earnings per share. Sell-side analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Analysts Set New Price Targets

PFE has been the subject of a number of analyst reports. Guggenheim reissued a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. Truist Financial cut their target price on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a report on Wednesday, December 18th. Bank of America reissued a “neutral” rating and issued a $29.00 target price on shares of Pfizer in a report on Tuesday, December 10th. Hsbc Global Res upgraded shares of Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. Finally, UBS Group dropped their price target on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 8th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, six have issued a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $31.92.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.